47 results about "Citrate buffer" patented technology

The invention belongs to the technical field of stem cell biological preparations, and particularly relates to an anti-aging compound preparation based on stem cells and application of the anti-aging compound preparation in delaying skin aging. The composition is composed of an inner water phase, a middle oil phase and an outer water phase, wherein the inner water phase is prepared from the following components: stem cell exosomes, hyaluronic acid, nicotinamide ribose, trehalose, mannitol, glycine and a citric acid buffer solution; the medium oil phase is prepared from the following components: medium chain triglyceride, shea butter, vitamin E succinate, PEG (Polyethylene Glycol) modified ceramide NP and cholesterol succinic acid monoester; the external water phase is prepared from the following components: polydatin, cellulose nanocrystals and an emulsifying agent. On the basis of a W / O / W emulsion system, a multi-layer anti-aging mechanism is constructed by utilizing a three-dimensional delivery framework of an inner water phase, an oil phase and an outer water phase and space-time synergy of active ingredients, the exosome permeation efficiency is improved through microneedle introduction, and the anti-oxidation and barrier repair effects are achieved by using multiple ingredients.

The invention discloses a synthetic method of photosensitive composite hydrogel and application of the photosensitive composite hydrogel in treatment of periodontitis. The composition expression of the photosensitive composite hydrogel is MHA-B-coated Lipo, and the photosensitive composite hydrogel is prepared by the following steps: entrapping berberine hydrochloride by lipidosome with proton gradient, and then mixing with methacrylated hyaluronic acid, a photoinitiator and a cross-linking agent; according to the liposome with the proton gradient, a citric acid buffer solution is adopted for preparing blank liposome, and then alkali liquor is used for adjusting the pH value of an external phase to be alkalescent, so that the transmembrane gradient is formed. The liposome is used as a drug delivery carrier, berberine is entrapped in the liposome and is combined with the MHA hydrogel to form a composite sustained-release drug, and the composite sustained-release drug has the advantages of strong targeting property, good responsiveness, good biocompatibility and high biological safety; and the hydrogel has injectable and photosensitive cross-linking characteristics, is suitable for clinical minimally invasive operation, has the advantages of accurate immune regulation and control, and has a wide application prospect.

The invention relates to the technical field of biological pharmacy, and discloses a preparation method of a ready-to-use stable 3D-MLA adjuvant solution, which comprises the following steps: dissolving citric acid monohydrate and trisodium citrate dihydrate in water for injection to prepare a citrate buffer solution; adding polysorbate 80 into the citrate buffer solution while stirring, and dissolving the polysorbate 80; adding 3D-MLA into the obtained solution under stirring, and dissolving the 3D-MLA; adjusting the pH value of the solution; fixing the volume by using water for injection; sterilizing and filtering through a filter membrane, filling a container with filtrate, and sealing; and refrigerating and storing. According to the present invention, the citrate buffer solution is adopted, the pH value of the adjuvant solution is adjusted, and the combination effect of the buffer system and the pH environment is utilized, such that the chemical degradation of the 3D-MLA in the injection water is effectively inhibited, the technical problem that the solution is easily degraded is solved, and the ready-to-use preparation capable of maintaining the stability under the refrigeration storage condition is obtained.

The invention discloses a lipid nano-micelle preparation method, which comprises: (1) providing an amphiphilic lipid alcoholic solution with a concentration of 20-50 mg / mL and a buffer solution, the buffer solution being selected from a PBS buffer solution, a citrate buffer solution, a Tris-HCl buffer solution or an acetate buffer solution; (2) mixing the alcoholic solution of the amphiphilic lipid and a buffer solution according to the flow velocity ratio of the alcoholic solution of the amphiphilic lipid to the buffer solution of (2-4): 1 by adopting microfluidic mixing equipment to obtain a mixed product; and (3) carrying out liquid change on the mixed product by using a buffer solution to remove the alcohol solvent. On the premise of ensuring the small particle size of the lipid nano-micelle, the uniformity and narrow particle size distribution of the lipid nano-micelle are improved, and the target of batch-to-batch reproducibility is achieved. The method does not need to use dangerous chemicals, is high in safety, is simple to operate, is low in amplification production difficulty by combining a microfluidic technology with a liquid change technology, is low in energy consumption, can effectively improve the production efficiency, and reduces the production cost.

The application discloses a cysteine-rich protein 61 antigen storage solution, which comprises a protein protective agent, a non-ionic surfactant, a preservative, a soluble metal salt, a sugar substance and a buffer solution, wherein the buffer solution is a citric acid-citrate buffer solution, and the storage solution further comprises polyethylene glycol and polyvinylpyrrolidone; the pH value of the storage solution is in the range of 5.0-5.5; the added mass of the polyvinylpyrrolidone is 1.0-1.5 times of the mass of the polyethylene glycol; and the protein protective agent at least contains serum. The storage solution can stably store the cysteine-rich protein 61 antigen, and the cysteine-rich protein 61 antigen can be stably stored for 12 months at 2-8 DEG C and for 7 days at 37 DEG C, thereby solving the inconvenience caused by the freeze-drying storage of Cyr61 protein due to the stability and providing important support for Cyr61 as a new marker for subsequent clinical application.

This invention belongs to the field of active ingredient extraction technology, and relates to a compound algae extract, its preparation method, and its application. The preparation method includes: S1. Taking algae raw materials and soaking them in a citrate-citrate buffer solution with a pH of 3-5 at 60-80°C; S2. Cooling the obtained treated material to 50-55°C, and then performing enzymatic hydrolysis and enzyme inactivation to obtain an enzymatic hydrolysate; S3. Filtering the enzymatic hydrolysate and collecting the filtrate; S4. Performing ultrafiltration on the filtrate to obtain a concentrated solution; S5. Sterilizing and drying the concentrated solution to obtain the compound algae extract. This invention utilizes a citrate-citrate buffer solution with a specific pH range combined with enzymatic hydrolysis and ultrafiltration to extract active ingredients from algae while removing residual heavy metals, achieving a high yield of algae extract and a high heavy metal removal rate. This compound algae extract can play a dual role in anti-inflammatory and tablet adhesion in bone and joint health care compositions.

The purpose of the present disclosure is to provide a protective agent excellent in a protective effect of a phospholipid membrane. This liquid composition for protecting a phospholipid membrane comprises (A) a magnesium salt, (B) an acetate buffer solution, a citrate buffer solution, a carbonate buffer solution, and / or a succinate buffer solution, and preferably further contains at least any of (C) a polyhydric alcohol, (D) a saccharide and / or a sugar alcohol, (E) polyethylene glycol, and (F) an amino acid. The liquid composition for protecting the phospholipid membrane is excellent in the protective effect of the phospholipid membrane.

The invention belongs to the technical field of active ingredient extraction, and relates to a composite algae extract as well as a preparation method and application thereof, the preparation method comprises the following steps: S1, taking an algae raw material, and carrying out immersion treatment by adopting a citric acid-citrate buffer solution with the pH value of 3-5 at 60-80 DEG C; s2, cooling the treated material obtained in the step S2 to 50-55 DEG C, and then performing enzymolysis and enzyme deactivation to obtain enzymatic hydrolysate; s3, after the enzymatic hydrolysate is filtered, filtrate is collected; s4, carrying out ultrafiltration treatment on the filtrate to obtain a concentrated solution; and S5, sterilizing and drying the concentrated solution to obtain the composite algae extract. According to the method, the citric acid-citrate buffer solution with a specific pH value range is combined with enzymolysis and ultrafiltration, so that residual heavy metals can be removed while active components in the algae are extracted, and the method has relatively high algae extract yield and heavy metal removal rate and is suitable for industrial production. The composite algae extract can play a dual role in anti-inflammation and tablet adhesion in the bone joint health-care preparation.

The invention relates to the field of biomedical technologies and pharmaceutical preparations, and discloses a TLR9 + HA201 composite adjuvant and a preparation method and application thereof, and the TLR9 + HA201 composite adjuvant freeze-drying preparation comprises the following components: a TLR9 + HA201 composite adjuvant, a TLR9 + HA201 composite adjuvant, a TLR9 + HA201 composite adjuvant freeze-drying agent, a TLR9 + HA201 composite adjuvant freeze-drying agent, a TLR9 D-(+)-trehalose; l-glutamic acid; a citrate buffer solution; the pH value of the aqueous solution to be freeze-dried is 6.5-7.5, the concentration of the D-(+)-trehalose is 8% w / v-12% w / v, the concentration of the L-glutamic acid is 0.8% w / v-1. 5% w / v, and the concentration of the citrate buffer solution is 15-25 mM. Through the synergistic effect of D-(+)-trehalose and L-glutamic acid in a specific citrate buffer system, efficient protection on the biological activity of the TLR9 + HA201 composite adjuvant is achieved, and the freeze-dried preparation shows the immune activation ability basically consistent with that before freeze-drying after being redissolved.

The present application relates to the technical field of nasal spray, in particular to a kind of nasal use of shangxiangyuan leaf composite spray and its preparation process.The preparation process includes the following steps: the system mass ratio is 1.5-2% of nano microspheres, 2.5-3% of glycerol, 0.3-0.5% of hydroxyethyl cellulose, 0.2-0.3% of phenoxyethanol and 20-25% of citrate buffer are mixed and the rest is made up with pure water, stirred until uniform, encapsulated to obtain nasal use of shangxiangyuan leaf composite spray.The present application carries out esterification reaction of glycerophosphocholine and lauric acid to synthesize glycerophosphocholine-lauric acid ester, glycerophosphocholine-lauric acid ester is the skeleton structure with glycerol, and ester bond is formed, so that glycerophosphocholine retains the structure of glycerophosphocholine while introducing the long chain of lauric acid, has better bioavailability and lower mucous membrane irritation, and provides stable structure and encapsulation efficiency for subsequent formation of liposome coating structure and loading shangxiangyuan leaf extract.

The invention provides a canine distemper vaccine as well as a preparation method and application thereof, and the method comprises the following steps: designing mRNA vaccine template plasmids aiming at canine distemper virus H protein by taking pUC57 as a carrier; carrying out single enzyme digestion on the mRNA vaccine template plasmid, and recovering a single enzyme digestion product; carrying out RNA in-vitro transcription on the single enzyme digestion product to obtain a transcribed RNA stock solution; the RNA stock solution is purified, the purified RNA is dissolved, and HmRNA is obtained; the method comprises the following steps: adding H mRNA into a citric acid buffer solution to obtain an mRNA-citric acid buffer solution, preparing an LNP premixed solution, and mixing the mRNA-citric acid buffer solution and the LNP premixed solution to obtain the H mRNA-LNP. The canine distemper vaccine prepared by the invention has the advantages of high flexibility, high preparation speed and capability of simultaneously causing the organism to generate humoral immunity and cellular immunity.

The invention relates to the technical field of environmental governance, in particular to a composite biological enzyme deodorant and a preparation method thereof.The preparation method comprises the following steps that S1, microbial flora with a deodorization function is selected for pretreatment, and composite biological enzyme liquid is obtained; s2, adding saccharides, glycerol and EDTA-2Na (Ethylene Diamine Tetraacetic Acid-2Na) into the composite biological enzyme liquid obtained in the S1 to form a mixed liquid; s3, soaking the humic acid particles in purified water, performing ultrasonic extraction, and performing microporous filtration to obtain activated humic acid liquid; s4, adding the activated humic acid liquid obtained in the step S3 into the mixed liquid obtained in the step S2, and stirring and mixing; s5, adding the residual citrate buffer solution to obtain a semi-finished product mixed solution A; s6, complementing purified water, and uniformly stirring and mixing to obtain a finished product of the composite biological enzyme deodorant. According to the invention, through the synergistic effect of the composite bio-enzyme and humic acid and the stable support of a multi-component protection system, the comprehensive effects of efficient deodorization, component stability and environmental adaptability are realized, and no secondary pollution is caused.

The present invention relates to an IgM antibody formulation and uses thereof. In particular, the IgM antibody formulation comprises an IgM antibody, which is an IgM antibody formed by a nanobody fusion protein and a J chain, the nanobody fusion protein is a fusion protein comprising a nanobody and an Fc fragment, which are optionally linked by a linker, wherein the formulation further comprises a buffer selected from a citrate buffer system, optionally the formulation further comprises one or more of a stabilizer, an osmotic pressure regulator and a surfactant.

The invention discloses a nano drug-loaded nasal spray composition for treating nasosinusitis. The nano drug-loaded nasal spray composition is prepared from the following raw materials: nano silver, PVP (Polyvinyl Pyrrolidone), baicalin, flos magnoliae volatile oil, chitosan, PLGA (Poly (Lactic-co-Glycolic Acid), sodium hyaluronate, a citrate buffer solution and the balance of sterile normal saline. The invention also discloses a preparation method of the nano drug-loaded nasal spray composition for treating nasosinusitis, the preparation method comprises the following steps: firstly preparing PVP modified nano silver suspension, then preparing baicalin nanoparticles and magnolia flower volatile oil nanoparticles by adopting an emulsification-solvent evaporation method, and PVP is used as a stabilizer of nano silver to ensure the long-term dispersion stability of nano silver, so that the stability of the nano silver is ensured, and the stability of the nano silver is ensured. Finally, all the components are mixed in a sterile operation table, the pH is adjusted, filtration sterilization is conducted through a 0.22-micron sterile filter membrane, terminal sterilization is conducted through gamma-ray irradiation after split charging is conducted, and the final product can be prepared into quantitative spray or sterile nose drops to meet different clinical requirements.

The present invention relates to a pharmaceutical composition comprising a radiohybrid comprising a fluorinated silicon and a chelating group, wherein either the fluorine is 18 F, or the chelating group comprises a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg / mL ethanol; and 5-10 mg / mL sodium chloride.

The invention relates to the field of biomedicine, in particular to an oral cancer screening and prognosis kit based on detection of phosphorylated Cofilin protein expression level and application of the oral cancer screening and prognosis kit. The kit contains xylene, alcohol, a citrate buffer solution, hydrogen peroxide, a confining liquid, a primary antibody, a secondary antibody, a DAB developing solution, hematoxylin and neutral gum. According to the kit, the malignant process of the oral squamous cell carcinoma is judged by detecting the expression level of the phosphorylated Cofilin protein in the oral mucosa tissue of a human body, the kit is used for auxiliary diagnosis of clinical oral squamous cell carcinoma, an effective theoretical basis is provided for taking targeted blocking measures or decisions for patients, and the clinical application and transformation prospects are good.

The present invention provides a formulation that includes a therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof, and a method for preparing the formulation. In some embodiments, the formulation includes a tonicity agent, a citrate buffer, water, and has an initial pH of from 5.6 to 6.0. In other embodiments, the formulation includes a tonicity agent, a citrate buffer, an antioxidant, water, and has an initial pH of from 3.6 to 4.8. The formulation of the invention is sterile, stable, ready-to-administer and packaged into a polymeric syringe.

The present disclosure relates to a pharmaceutical composition comprising a bispecific antibody that specifically binds to GUCY2C and CD3. In particular, the disclosure relates to a pharmaceutical composition comprising a bispecific antibody that specifically binds to GUCY2C and CD3 and a buffer, which is a histidine buffer, an acetate buffer, a citrate buffer, a succinate buffer, or a Tris salt buffer.

The invention relates to a cordyceps militaris extract and an extraction process thereof, and belongs to the technical field of traditional Chinese medicine extraction. The extraction efficiency is improved through the synergistic effect of enzymolysis, pulse ultrasound and supercritical extraction. The method specifically comprises the following steps: mixing a cordyceps militaris raw material with cellulase and pectinase for enzymolysis, and adding a protective agent containing glutathione and ascorbic acid and an ethanol-citrate buffer solution under the protection of inert gas for pulse ultrasonic treatment; and concentrating the extracting solution, performing supercritical CO2 extraction to remove fat-soluble impurities, and performing freeze drying to obtain the extract. The cordycepin content of the obtained extract is larger than or equal to 0.8%, and the mass ratio of cordycepin to cordycepic acid is stabilized to be 1: 0.2-1. The process solves the problems of serious damage to active components and low efficiency of a traditional method.

The invention discloses a nano iron oxide injection based on a synergistic stabilization mechanism and a preparation method of the nano iron oxide injection. The injection comprises nano iron oxide particles, carboxyl-terminated methoxypolyethylene glycol, an amino acid stabilizer, a citrate buffer agent and an isotonic agent. The preparation method comprises the following steps: synthesizing an oleic acid modified nano iron oxide core; performing ligand exchange at 0-4 DEG C to form a PEG anchoring layer; then, under the temperature of 6-8 DEG C, through programmed feeding and low-temperature shearing, amino acid and citrate are synergistically embedded, and a stable structure is constructed. According to the invention, a triple stable system of PEG anchoring layer-synergistic chelating layer-buffer microenvironment is constructed, and a whole-course low-temperature controllable process is adopted, so that the defects of poor long-term stability, high iron ion release rate, poor process reproducibility and poor moist heat sterilization resistance of the existing nano iron oxide contrast agent are overcome. The obtained product has excellent colloidal stability, extremely low ion release rate and good biological safety, and is suitable for magnetic resonance imaging.

The present application relates to a kind of cordyceps militaris extract and its extraction process, belong to traditional Chinese medicine extraction technical field.The present application is through enzymolysis, pulse ultrasonic and supercritical extraction synergistic effect to improve extraction efficiency.Specifically including: cordyceps militaris raw materials and cellulase, pectinase mixed enzymolysis, under the protection of inert gas, adding the protective agent containing glutathione and ascorbic acid and ethanol-citrate buffer solution is treated by pulse ultrasonic;Extract liquid is concentrated after supercritical CO2 extraction removes fat-soluble impurities, freeze-drying obtains extract.The obtained extract cordycepin content is ≥0.8%, and the mass ratio of cordycepin and cordycepic acid is stably at 1:0.2-1.The process solves the problem of serious damage of active ingredient in traditional method, low efficiency.

The application relates to the technical field of biological pharmacy, and discloses a preparation method of a ready-to-use stable 3D-MLA adjuvant solution, which comprises the following steps: dissolving citric acid monohydrate and trisodium citrate dihydrate in water for injection to prepare a citrate buffer; under stirring, adding polysorbate 80 into the citrate buffer to dissolve the polysorbate 80; under stirring, adding 3D-MLA into the obtained solution to dissolve the 3D-MLA; adjusting the pH value of the solution; using water for injection to fix the volume; performing sterilization filtration through a filter membrane, filling the filtrate into a container and sealing the container; and cold storage. Through the citrate buffer and the adjustment of the pH value of the adjuvant solution, the combination of the buffer system and the pH environment effectively inhibits the chemical degradation of the 3D-MLA in the water for injection, the technical problem that the solution is prone to degradation is solved, and a ready-to-use preparation which can be stably stored under cold storage conditions is obtained.

The invention belongs to the technical field of crop genetic breeding, and provides a composite buffer solution, a seed polyploidy induction method and application, the composite buffer solution comprises a colchicine solution, a penetrant, a first buffer solution, a second buffer solution and a third buffer solution, the second buffer solution is a citrate buffer solution, and the third buffer solution is a tris (hydroxymethyl) aminomethane hydrochloride buffer solution; the pH value of the mixed first buffer solution, second buffer solution and third buffer solution is 6-7. The seed polyploidy induction method is suitable for diploid polygonatum sibiricum seeds, the toxicity of colchicine is neutralized and dark culture is carried out under the basic action of a composite buffer solution, so that normal growth and development of subsequent seeds are ensured, the stability of chromosome doubling is improved, and the induction efficiency and the success rate are further improved.

The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride and a chelating group wherein either the fluorine is 18F or the chelating group contains a chelated radioactive metal, wherein the composition has a ph of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg / ml ethanol; and 5-10 mg / ml sodium chloride.

The invention relates to the technical field of natural product extraction, in particular to a method for separating dihydromyricetin, myricetin and quercetin from raspberry tea and application, and the separation method comprises the following steps: pretreating raspberry tea powder, mixing with an extracting agent 1, an extracting agent 2 and an extracting agent 3 in sequence, and carrying out ultrasonic treatment, suction filtration, concentration and purification to obtain dihydromyricetin, myricetin and quercetin; the extracting agent 1 comprises an ethanol solution with the volume concentration of 50%-55% and a citrate buffer solution; the extracting agent 2 comprises an ethanol solution with the volume concentration of 40%-45% and a phosphate buffer solution; and the extracting agent 3 comprises an ethanol solution with the volume concentration of 75-80% and a sodium hydroxide solution. According to the physical and chemical properties of dihydromyricetin, myricetin and quercetin, an extracting agent with specific ethanol solution concentration and pH is set to adapt to the physical and chemical properties (polarity, heat sensitivity, pH sensitivity and the like) of the dihydromyricetin, myricetin and quercetin, and the defects of low separation efficiency and large activity loss of a traditional process are overcome.

The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing silicon fluoride and a chelating group wherein the fluorine is 18F or the chelating group contains a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg / mL ethanol; and 5-10 mg / mL sodium chloride.

An improved adenovirus formulation comprising: a) a recombinant adenovirus; b) a citrate buffer; c) a cyclodextrin compound; and d) a salt, said formulation having a pH ranging from about 5.5 to about 6.5, and wherein said formulation is free of non-ionic detergent. The invention also relates to a method of preserving an adenovirus which comprises preparing said formulation.

The invention provides a pharmaceutical composition for preventing and / or treating tetanus as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a recombinant tetanus toxin C fragment as a unique antigen component, an adjuvant and a solvent, wherein the adjuvant is selected from one or more of an aluminum adjuvant, a Toll-like receptor stimulant and saponin, preferably the aluminum adjuvant, and / or the solvent is selected from one or more of a phosphate buffer solution, a citrate buffer solution, a histidine salt buffer solution and a sodium chloride solution, preferably the phosphate buffer solution and / or the sodium chloride solution. The adopted recombinant tetanus natural C fragment (Hc) is non-toxic, formaldehyde inactivation is not needed, meanwhile, the possibility of toxicity reversion is avoided, and the pharmaceutical composition can induce mammals to generate high immune response against tetanus and has good immune persistence.

A detergent may include a citrate buffer. A detergent may include a surfactant component. A detergent may include a chelator component, wherein a pH of the detergent composition is in a range of from about 6.5 to about 9, and at least one of the citrate buffer, surfactant component and the chelator component are biodegradable.

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.